Biomarkers and Biologics: Advancing Selection and Monitoring of Targeted Therapies for Severe Asthma

Biomarkers and Biologics: Advancing Selection and Monitoring of Targeted Therapies for Severe Asthma is organized by Integrity Continuing Education Inc..,Release date: 09- 15- 2022,Expiration date: 09- 15- 2023,Program Overview:,Various biomarkers have emerged as important markers of type 2 inflammation and as indicators for severe asthma endotypes. Immunglobulin E (IgE), blood eosinophils, and fractional exhaled nitric oxide (FeNO) have high clinical applicability in particular, and are useful in predicting response to biologic therapies. This program will review the role of these biomarkers in asthma pathogenesis and the latest recommendations for their utility in selection of therapy and prediction of response. A series of case studies will be reviewed demonstrating the application of this information and guideline recommendations in practice to assist with advancing the management of patients with severe asthma. In addition, current recommendations for length of biologic trials in patients with severe asthma, evaluation of response to biologic therapy, and recommendations for biologic discontinuation or switching will be reviewed. Finally, recent real-world data on the frequency of biologic switching and experience of patients prescribed biologics will be presented to support the rationale for appropriate biologic trials and evaluation of response,Learning Objectives:,Upon completion of this educational activity, participants should be able to:,• Discuss the latest evidence related to the value of IgE, blood eosinophils, and FeNO in severe asthma phenotypes and their implications for therapeutic decision making,• Select appropriate biologic therapies for severe asthma based on phenotype, biomarkers, and comorbidities,• Apply current guidelines to the assessment of biologic therapy and considerations for switching or discontinuing therapy,Additional details will be posted as soon as information is available.